Abstract
Objective:To analyze the clinical effect of budesonide/fomoterol combined with montelukast in the treatment of chronic persistent asthma.Methods:Ninety-four patients with asthma who came to our hospital for treatment from April 2017 to April 2019 were randomly divided into control group and observation group, with 47 patients in each group. The control group was treated with budesonide/formoterol, and the observation group was treated with montelukast on the basis of the control group. The treatment effect of the two groups was observed and compared.Results:The total efficacy rate of the observation group was significantly higher than that of the control group (P<0.05); the daytime symptom score and nighttime symptom score of the observation group were significantly higher than those of the control group (P<0.05). The pulmonary function indexes of the two groups after treatment were significantly higher than that before treatment, and the improvement of the observation group was more significant (P<0.05); the FeNO and EO levels of the observation group after treatment were superior to those of the control group, and the difference was statistically significant (P<0.05).Conclusion:Budesonide/formoterol powder inhalation combined with montelukast can effectively improve the lung function, reduce the level of inflammatory factors, and accelerate the regression of symptoms in the treatment of chronic persistent asthma. It is worth clinical application.
Highlights
In recent years, the incidence of bronchial asthma has been increasing
They were divided into a control group and an observation group using the method of random number table, 47 each group
Therapeutic method: The control group was treated with budesonide/formoterol powder inhalation at a dosage of 160 μg/4.5μg (As-tra Zeneca AB, Sweden, specification: 160 μg/4.5 μg each inhalation), twice a day, for two weeks
Summary
The incidence of bronchial asthma has been increasing. Researches shows that the incidence of bronchial asthma is not caused by a single factor,[1,2,3] and its incidence involves many aspects such as the effects of inflammation and cytokines such as interleukin and tumor factors. The clinical manifestations of bronchial asthma are cough, asthma and dyspnea, which have a serious impact on the quality of life of patients.[4,5] Clinically, bronchial asthma is divided into acute attack period, chronic persistent period and clinical remission period. Previous clinical studies focused on acute attack period. With the improvement of medical environment and medical care, medical
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
